|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97显示文摘ALM To establish clone cells with different metastatic potential for the study of metastasis-related mechanisms. METHODS Cloning procedure was performed on parental hepatocellular carcinoma (HCC) cell line MHCC97. andbiological characteristics of the target clones selected by in vivo screening were studied.``RESULTS Two clones with high MHCC97-H and IowMHCC9--L1 metastatic potential were isolated from theparent cell line. Compared with MHCC97-L. MHCC97-H hadsmaller cell size average cell diameter 43 um vs 50 μmand faster in vitro and in vivo growth rate tumor celldoubling time was 34.2 h vs 60.0 h. The main ranges ofchromosomes were 5.5 58 in MHCC97-H and 57 62 inMHCC97-L. Boyden chamber in vitro invasion assay demonstrated that the number of penetrating cells through the artificial basement membrane was 137.5 - 11 .0) cellsfield for MHC_C99--H vs 17.7 - 6.3) field for MHCC97-L.The proportions of cells in GO Gl phase. S phase, and G_ M phase for MHCC97-H MHCC97-L were 0.56 6.65.0.28 0.25 and 0.l6 0.10, respectively, as measured by flow cytometry. The serum AFP levels in nude mice 5 wk after orthotopic implantation of tumor tissue were ( 24666 μg. L for MHCC97-H and (91- 66) μg' L 1 for MHCC97L. The pulmonary metastatic rate was 100% (10-10) vs40% 4- 10).``CONCLUSION Two clones of the same genetic background but with different biological behaviors were established, which could be valuable models for investigation on HCC metastasis. | Yan Li Zhao-You Tang Sheng-Long Ye Yin-Kun Liu Jie Chen Qiong Xue Jun Chen Dong-Mei Gao Wei-Hua Bao Liver Cancer Institute and Zhongshan Hospital of Fudan University (Former Liver Cancer Institute of Shanghai Medical University),Shanghai 200032,China | 2001 | World Journal of Gastroenterology2001，7，5： | 111 |
| 2 | Hepatocellular carcinoma: current management and recent advances显示文摘BACKGROUND: Hepatocellular carcinoma (HCC) is a major health problem worldwide. It is the fifth most common cancer in the world, and the third most common cause of cancer-related death. Without specific treatment, the prognosis is very poor. The goal of management is 'cancer control' - a reduction in its incidence and mortality as well as an improvement in the quality of life of patients with HCC and their families. This article aims to review the current management of HCC and its recent advances. DATA SOURCES: A MEDLINE database search was performed to identify relevant article using the keyworks 'hepatocellular carcinoma', 'hepatectomy', 'liver transplantation', and 'local ablative therapy'. Additional papers and book chapters were identified by a manual search of the references from the key articles. RESULTS: Liver resection and liver transplantation remain the options that give the best chance of a cure. Recent evidence suggests that local ablative therapy may offer comparable survival results in patients with small HCC, and preserved liver function. Transarterial chemoembolization (TACE) is the most promising palliative modality for unresectable HCC, but other techniques, such as transarterial radioembolization (TARE), and local ablative therapy, have also shown comparable results. CONCLUSIONS: Early diagnosis of HCC remains a key goal in improving the prognosis of patients. During the last two decades, operative mortality and surgical outcome of liver resection and liver transplantation for HCC have improved. Progress also has been made in multi-modality therapy which can increase the chance of survival and improve the quality of life for patients with advanced HCC. | Wan-Yee Lau Eric C. H. Lai | 2008 | Hepatobiliary & Pancreatic Diseases International2008，7，3： | 100 |
| 3 | Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma显示文摘BACKGROUND: Angiogenesis is known to be essential to the survival, growth, invasion, and metastasis of tumor cells. Vascular endothelial growth factor (VEGF) are an important angiogenic factor regulating tumor angiogenesis, but its significance and tumor pathologic features are un- clear in hepatocellular carcinoma (HCC). In the present study, we analyzed expression of tissue VEGF, alteration of microvascular density (MVD) in microvessel angiogenesis, development and metastasis of HCC, and level of serum VEGF in differential diagnosis of benign and malignant liv- er diseases. METHODS: Tumor specimens were prospectively collected from HCC patients undergoing resection. Total RNAs were extracted and the expression levels were detected from different parts of HCC tissues. The cellular distributions of VEGF and MVD of liver tumors and their paracancerous and distal cancerous tissues were investigated by streptavi- din peroxidase (S-P) immunohistochemistry, respectively. The VEGF levels of circulating blood and hepatoma tissues were measured by enzyme-linked immunosorbent assay. RESULTS: The incidence of VEGF expression was 63.9% in HCCs (23/36 cases), 78.3% in non-encapsulated HCCs (18/23), and 90.9% in HCCs with extrahepatic metastasis (10/11), respectively. The VEGF expression was tightly correlated with MVD (P <0.01). The MVD in HCC with metastasis, low differentiation or non-encapsulation was significantly higher than that in HCC with intact capsule, high differentiation, or no metastasis. No significant diffe- rence was found between VEGF, MVD, tumor size, and hepatitis virus infection. The level of total RNA in HCC tis- sues was significantly lower but the VEGF level significantly higher than those in paracancerous or distal cancerous ones (P<0.01). The abnormal expression levels of VEGF in sera of HCC patients were directly correlated with the me- tastasis and recurrence of tumors. CONCLUSION: The high expression of VEGF and abnor- mality of tissue MVD are useful predictors for vascular inva- sion and metastasis of liver tumors. | Deng-Fu Yao, Xin-Hua Wu, Yong Zhu, Gong-Sheng Shi, Zhi-Zhen Dong, Deng-Bing Yao, Wei Wu, Li-Wei Qiu and Xian-Yong Meng Nantong, China Research Center of Clinical Molecular Biology , Department of Pathology and Department of Gastroenterology , Affiliated Hos- pital of Nantong University Department of Diagnostics , and Institute of Neurosciences , Nantong University Nantong 226001, China | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，2： | 81 |
| 4 | Esophageal cancer: Risk factors,screening and endoscopic treatment in Western and Eastern countries显示文摘Esophageal cancer is one of the most unknown and deadliest cancers worldwide,mainly because of its extremely aggressive nature and poor survival rate.Esophageal cancer is the 6th leading cause of death from cancer and the 8th most common cancer in the world.The 5-year survival is around 15%-25%.There are clear differences between the risk factors of both histological types that affect their incidence and distribution worldwide.There are areas of high incidence of squamous cell carcinoma(some areas in China) that meet the requirements for cost-effectiveness of endoscopy for early diagnosis in the general population of those areas.In Europe and United States the predominant histologic subtype is adenocarcinoma.The role of early diagnosis of adenocarcinoma in Barrett's esophagus remains controversial.The differences in the therapeutic management of early esophageal carcinoma(high-grade dysplasia,T1 a,T1 b,N0) between different parts of the world may be explained by the number of cancers diagnosed at an early stage.In areas where the incidence is high(China and Japan among others) early diagnoses is more frequent and has led to the development of endoscopic techniques for definitive treatment that achieve very effective results with a minimum number of complications and preserving the functionality of the esophagus. | María José Domper Arnal ángel Ferrández Arenas ángel Lanas Arbeloa | 2015 | World Journal of Gastroenterology2015，21，26： | 116 |
| 5 | 中国早期食管鳞状细胞癌及癌前病变筛查与诊治共识(2015年,北京)显示文摘食管癌作为发病率较高的恶性肿瘤之一已越来越被人们重视,其发病率在全球范围居恶性肿瘤第8位,在我国大陆居各类肿瘤第5位,其死亡率在全球范围居恶性肿瘤第6位,在我国大陆居第4位。我国食管癌以食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC;简称食管鳞癌)为主,占食管癌90%以上,其次为食管腺癌(esophageal adenocarcinoma,EAC)。自20世纪70年代以来,西方国家食管腺癌的发病率逐渐升高,已超过鳞癌,成为食管癌主要类型;而我国一直以食管鳞癌为主,腺癌发病率未见明显增长。我国食管鳞癌的发病有明显的地区差异性,一定地域的绝对高发与周边地区的相对低发构成了我国食管鳞癌最典型的流行病学特征。 | 无 | 2016 | 中华消化内镜杂志2016，33，1： | 100 |
| 6 | 原发性肝癌诊疗规范(2017年版)显示文摘原发性肝癌是目前我国第四位的常见恶性肿瘤及第三位的肿瘤致死病因,严重威胁我国人民的生命和健康。原发性肝癌主要包括肝细胞癌(Hepatocellular Carcinoma,HCC)。 | | 2017 | 传染病信息2017，30，3： | 122 |
| 7 | 2018年欧洲肝脏研究学会(EASL)肝细胞癌临床实践指南推荐要点显示文摘肝细胞癌(hepatocellular carcinoma,HCC)的发病率和死亡率在世界范围内仍居高不下,且呈全球化增长的趋势。欧洲肝脏研究学会(EASL)最近发布了2018年版肝细胞癌临床实践指南,依据近年来大量最新循证医学证据,对2012年EASL与欧洲癌症治疗研究组织(EORTC)联合发布的肝细胞癌诊疗指南进行全面更新和充实,旨在优化HCC患者的诊断和治疗。 | 薛同春 叶胜龙 | 2018 | 胃肠病学和肝病学杂志2018，27，6： | 461 |
| 8 | Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma:a prospective non.randomized study显示文摘Background: Transarterial chemoembolization(TACE) is recommended as the standard care for unresectable hepatocellular carcinoma(HCC) at Barcelona Clinic Liver Cancer(BCLC) stage A-B. However, the efficacy of TACE on large(> 10 cm) stage A-B HCC is far from satisfactory, and it is proposed that hepatic artery infusion chemotherapy(HAIC)might be a better first-line treatment of this disease. Hence, we compared the safety and efficacy of HAIC with the modified FOLFOX(mFOLFOX) regimen and those ofTACE in patients with massive unresectable HCC.Methods: A prospective, non-randomized, phase II study was conducted on patients with massive unresectable HCC. The protocol involved HAIC with the mFOLFOX regimen(oxaliplatin, 85 mg/m^2 intra-arterial infusion; leucovorin,400 mg/m^2 intra-arterial infusion; and fluorouracil, 400 mg/m2 bolus infusion and 2400 mg/m^2 continuous infusion)every 3 weeks and TACE with 50 mg of epirubicin, 50 mg of lobaplatin, 6 mg of mitomycin, and lipiodol and polyvinyl alcohol particles. The tumor responses, time-to-progression(TTP), and safety were assessed.Results: A total of 79 patients were recruited for this study: 38 in the HAIC group and 41 in the TACE group. The HAIC group exhibited higher partial response and disease control rates than did the TACE group(52.6% vs. 9.8%, P < 0.001;83.8% vs. 52.5%, P = 0.004). The median TTPs for the HAIC and TACE groups were 5.87 and 3.6 months(hazard radio[HR] = 2.35,95% confidence interval [CI] = 1.16-4.76, P = 0.015). More patients in the HAIC group than in the TACE group underwent resection(10 vs. 3,P = 0.033). The proportions of grade 3-4 adverse events(AE) and serious adverse events(SAE) were lower in the HAIC group than in the TACE group(grade 3-4 AEs: 13 vs. 27, P = 0.007;SAEs: 6 vs. 15,p = 0.044). More patients in the TACE group than in the HAIC group had the study treatment terminated early due to intolerable treatment-related adverse events or the withdrawal of consent(10 vs. 2,P = 0.026).Conclusions: HAIC with mFOLFOX yielded significantly better treatment responses and less serious toxicity than did TACE. HAIC might represent a feasible and promising first-line treatment for patients with massive unresectable HCC. | Min-Ke He Yong Le Qi-Jiong Li Zi-Shan Yu Shao-Hua Li Wei Wei Rong-Ping Guo Ming Shi | 2017 | Chinese Journal of Cancer2017，36，12： | 95 |
| 9 | 甲状腺癌诊疗规范(2018年版)显示文摘甲状腺癌(thyroid cancer)是一种起源于甲状腺滤泡上皮或滤泡旁上皮细胞的恶性肿瘤,也是头颈部最为常见的恶性肿瘤。近年来,全球范围内甲状腺癌的发病率增长迅速,据全国肿瘤登记中心的数据显示,我国城市地区女性甲状腺癌发病率位居女性所有恶性肿瘤的第4位。我国甲状腺癌将以每年20%的速度持续增长。根据肿瘤起源及分化差异,甲状腺癌又分为:甲状腺乳头状癌(papillary thyroid carcinoma,PTC)、甲状腺滤泡癌(follicular thyroid carcinoma,FTC)、甲状腺髓样癌(medullary thyroid carcinoma,MTC)以及甲状腺未分化癌(anaplastic thyroid cancer,ATC)。 | 中华人民共和国国家卫生健康委员会 | 2019 | 中华普通外科学文献(电子版)2019，13，1： | 433 |
| 10 | 原发性肝癌诊疗规范(2017年版)显示文摘1概述原发性肝癌是目前我国第四位的常见恶性肿瘤及第三位的肿瘤致死病因,严重威胁我国人民的生命和健康[1,2]。原发性肝癌主要包括肝细胞癌(hepatocellular carcinoma,HCC)、肝内胆管癌(intrahepatic cholangiocarcinoma,ICC)和HCC-ICC混合型三种不同病理类型,三者在发病机制、生物学行为、组织学形态、治疗方法以及预后等方面差异较大,其中肝细胞癌占到85%以上,因此本规范中的“肝癌”指肝细胞癌。 | 中华人民共和国卫生和计划生育委员会 | 2017 | 肿瘤综合治疗电子杂志2017，3，4： | 102 |
| 11 | 胃癌诊疗规范(2018年版)显示文摘一、概述胃癌(Gastric Carcinoma)是指原发于胃的上皮源性恶性肿瘤。在我国胃癌发病率仅次于肺癌居第二位,死亡率排第三位。全球每年新发胃癌病例约120万,中国约占其中的40%。我国早期胃癌占比很低,仅约20%,大多数发现时已是进展期,总体5年生存率不足50%。近年来随着胃镜检查的普及,早期胃癌比例逐年增高。 | 无 | 2019 | 中华消化病与影像杂志(电子版)2019，9，3： | 379 |
| 12 | Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma:A literature review显示文摘Hepatoid adenocarcinoma (HAC) is a rare but important special type of extrahepatic adenocarcinoma with clinicopathological presentation mimicking hepatocellular carcinoma (HCC), and prompt and correct diagnosis can be a challenge, especially in endemic areas with a high incidence of HCC. To date, HAC has only been reported in case series or single case reports, so we aimed to review the clinicopathological characteristics of HAC to obtain a more complete picture of this rare form of extrahepatic adenocarcinoma. All the articles about HAC published from 2001 to 2011 were reviewed, and clinicopathological findings were extracted for analysis. A late middle-aged male with high serum α-fetoprotein and atypical image finding of HCC should raise the suspicion of HAC, and characteristic pathological immunohistochemical stains can help with the differential diagnosis. Novel immunohistochemical markers may be useful to clearly differentiate HAC from HCC. Once metastatic HAC is diagnosed, the primary tumor origin should be identified for adequate treatment. The majority of HAC originates from the stomach, so panendoscopy should be arranged first. | Jiann-Sheng Su Yu-Tso Chen Ren-Ching Wang Chun-Ying Wu Shou-Wu Lee Teng-Yu Lee | 2013 | World Journal of Gastroenterology2013，19，3： | 75 |
| 13 | 原发性肝细胞癌经导管肝动脉化疗性栓塞治疗技术操作规范专家共识显示文摘原发性肝细胞癌(hepatocellular carcinoma,HCC,以下简称肝癌)是起源于肝细胞的恶性肿瘤。在中国,85%~90%是在肝炎后肝硬化的基础上发生。肝癌是一种富血供肿瘤,90%以上的血供来源于肝动脉。用加入化疗药物的栓塞剂栓塞肿瘤供血动脉,称经导管的肝动脉化疗性栓塞(transcatheter arterial chemoembolization,TACE)。这种治疗方法一方面阻断肿瘤血供,同时在肿瘤局部聚集高浓度的化疗药物, | | 2011 | 中华放射学杂志2011，45，10： | 65 |
| 14 | Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21^(WAF1) expression and hepatic apoptosis显示文摘AIM To detect the expression of caspase 3gene in primary human hepatocellular carcinoma(HCC)and investigate its relationship to p21WAF1gene expression and HCC apoptosis.METHODS In situ hybridization was employedto determine caspase 3 and p21WAF1expression inHCC.In situ end-labeling was used to detecthepatocytic apoptosis in HCC.RESULTS Twenty-one of 39(53.8%)cases ofHCC were found to express caspase 3transcripts,while 45.2% of HCC failed toexpress caspase 3.Non-cancerous adjacent livertissues showed more positive caspase 3(87.5%,7/8)as compared with HCC(P<0.05).The expression of caspase 3 is correlated withHCC differentiation,72.2%(13/18)ofmoderately to highly differentiated HCC showedcaspase 3 transcripts positive,while only 38.1%of poorly differentiated HCC harbored caspase 3transcripts(P<0.05).No relationship wasfound between caspase 3 expression and tumorsize or grade or metastasis,although 52.5%(5/8)of HCC with metastasis were caspase 3positive and a little higher than that with nometastasis(51.6%,P>0.05).Expression of caspase 3 alone did not affect the apoptosisindex(AI)of HCC.The AI was 7.12%o in caspase3-positive tumors(n=21),while in caspase 3-negative cases(n=18)6.59%0(P>0.05).Expression of caspase 3 clearly segregated withp21WAF1positive tumors as compared withp21WAF1-negative cases(16 of 23,69.6% versus5 of 16,31.3%)with statistical significance(P=0.017).In the cases with positive caspase 3and negative p21WAF1,the Al was found slightlyhigher,but with no statistical significance,thanthat with expression of p21WAF1and caspase 3(7.21‰ vs 6.98‰,P>0.05).CONCLUSION Loss of caspase 3 expressionmay contribute to HCC carcinogenesis,althoughthe expression of caspase 3 does not correlatewell with cell apoptosis in HCC.p21WAF1may bemerely one of the inhibitors which can reducecaspase 3 mediated cell apoptosis in HCCs. | Bao Hua Sun Jun Zhang Bao JǜWang Xi Ping Zhao You Kun Wang Zhi Qun Yu Dong Liang Yang Lian Jie Hao Department of Clinical Immunology,Tongji Hospital,Tongji Medical University,Wuhan 430030,Hubei Province,China | 2000 | World Journal of Gastroenterology2000，6，3： | 65 |
| 15 | Current and future treatments for hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) represents a unique challenge for physicians and patients.There is no definitively curative treatment.Rather,many treatment and management modalities exist with differing advantages and disadvantages.Both current guidelines and individual patient concerns must be taken into account in order to properly manage HCC.In addition,quality of life issues are particularly complex in patients with HCC and these concerns must also be factored into treatment strategies.Thus,considering all the options and their various pros and cons can quickly become complex for both clinicians and patients.In this review,we systematically discuss the current treatment modalities available for HCC,detailing relevant clinical data,risks and rewards and overall outcomes for each approach.Surgical options discussed include resection,transplantation and ablation.We also discuss the radiation modalities:conformal radiotherapy,yttrium 90 microspheres and proton and heavy ion radiotherapy.The biologic agent Sorafenib is discussed as a promising new approach,and recent clinical trials are reviewed.We then detail currently described molecular pathways implicated in the initiation and progression of HCC,and we explore the potential of each pathway as an avenue for drug exploitation.We hope this comprehensive and forward-looking review enables both clinicians and patients to understand various options and thereby make more informed decisions regarding this disease. | Alexander Schlachterman Willie W Craft Jr Eric Hilgenfeldt Avir Mitra Roniel Cabrera | 2015 | World Journal of Gastroenterology2015，21，28： | 76 |
| 16 | 甲状腺结节影像检查流程专家共识显示文摘甲状腺结节临床多见,4%人群体检可触及结节,50%人群行超声检查可发现结节,50%尸检能够发现结节,其中5%的甲状腺结节为恶性[1-4]。甲状腺恶性肿瘤包括原发性甲状腺癌、转移癌和肉瘤,其中绝大多数为原发性甲状腺癌,日常生活及工作中提及的甲状腺恶性结节多指原发性甲状腺癌。依据组织构成,原发性甲状腺癌分为乳头状甲状腺癌(papillary thyroid carcinoma,PTC)、滤泡细胞癌、髓样癌及未分化癌,其中 PTC 占80%~88%[5-6]。经外科手术和131I治疗,甲状腺癌的5年生存率达97%[7],10年生存率达96%[8],对于低危的PTC,5年和10年生存率可达近100%[9-10]。30%~90%的PTC在确诊时伴有颈部淋巴结转移[11],淋巴结转移是局部复发的重要风险因子,其危害较原发灶更为严重。因此,依据临床资料及影像特征,尽早将少数原发性甲状腺癌从众多的良性结节中鉴别出来,并对其进行分期、预测侵袭性和随访,对制定治疗方案和改善预后均具有重大意义。目前,针对甲状腺结节主要的影像检查方法包括超声、超声引导下细针穿刺细胞学检查(fine needle aspiration cytology,FNAC)、CT、MRI和核素检查等,这些检查方法各有优势及不足,制定合理的影像检查流程至关重要。为此,中华医学会放射学分会头颈学组和《中华放射学杂志》编辑部组织影像科、核医学科、超声科、内科和外科相关专家,经过多次讨论,形成了此版甲状腺结节影像检查流程专家共识供广大临床和影像医师参考,今后还将根据大家的反馈不断完善和改进。 | | 2016 | 中华放射学杂志2016，50，12： | 70 |
| 17 | 上尿路尿路上皮癌诊断与治疗中国专家共识显示文摘上尿路尿路上皮癌(upper tract urothelial carcinoma,UTUC)包括肾盂癌和输尿管癌,与膀胱癌同属尿路上皮癌。根据对欧美人群的研究报道,UTUC占全部尿路上皮癌的5%~10%,而在中国这一比例可能更高(2018年全国32家中心住院患者的初步调查结果显示,UTUC占尿路上皮癌的比例为9.3%~29.9%,平均17.9%)。UTUC的病因被认为与遗传(如Lynch综合征)、镇痛药物使用(如非那西汀)、职业接触(如接触芳香胺的行业)、吸烟,以及巴尔干肾病和马兜铃酸肾病相关,其具体的起病机制还有待进一步的研究。 | 中国医师协会泌尿外科医师分会肿瘤专业委员会 中国医师协会泌尿外科医师分会上尿路尿路上皮癌(CUDA-UTUC)协作组 医师分会上尿路尿路上皮癌(CUDA-UTUC)协作组 | 2018 | 中华泌尿外科杂志2018，39，7： | 77 |
| 18 | Nasopharyngeal carcinoma incidence and mortality in China,2013显示文摘Background: We estimated the incidence and mortality of nasopharyngeal carcinoma(NPC) in China in 2010 according to the data of 145 domestic population-based cancer registries in 2014, and no such reports since then.Hence, to further and better understand its epidemiology in China and to provide more precise scientific information for its control and prevention in China, we analyzed the NPC incidence and mortality of 255 domestic populationbased cancer registries, and estimated the national rates in 2013 again.Methods: NPC incidence and mortality data of 255 domestic cancer registries in 2013, accepted by the 2016 National Cancer Registry Annual Report, were collected and collated, and the indices of NPC such as the numbers of new cases and deaths, crude rates, age-standardized rates, and truncated rates of incidence and mortality were calculated and analyzed. The incidence and mortality in China and its constituent areas were estimated according to the national population in 2013.Results: An estimated 42,100 new cases and 21,320 deaths were attributed to NPC in China in 2013, accounting for1.14% of all new cancer cases and 0.96% of all cancer-related deaths that year in China. Crude incidence and mortality of NPC were 3.09/100,000 and 1.57/100,000, respectively. World age-standardized incidence and mortality were2.17/100,000 and 1.08/100,000, respectively. The incidence and mortality of males were obviously higher than those of females and slightly higher in urban areas than in rural areas. Among seven Chinese administrative regions, NPC incidence and mortality were obviously higher in South China than in other regions and lowest in North China. Top3 incidence and mortality provinces and registering areas all located in South China. The age-specific incidence and mortality rose quickly from age 25-29 and 35 to 39 years, respectively, peaked at different ages and varied by location.Conclusions: These results demonstrated that NPC incidence and mortality in China in 2013 were also at high levels worldwide, which suggested that its control and prevention should be enhanced. | Kuang-Rong Wei Rong-Shou Zheng Si-Wei Zhang Zhi-Heng Liang Zhu-Ming Li Wan-Qing Chen | 2017 | Chinese Journal of Cancer2017，36，12： | 73 |
| 19 | Immune suppression in chronic hepatitis B infection associated liver disease: A review显示文摘Hepatitis B virus(HBV) infection is one the leading risk factors for chronic hepatitis, liver fibrosis, cirrhosis and hepatocellular cancer(HCC), which are a major global health problem. A large number of clinical studies have shown that chronic HBV persistent infection causes the dysfunction of innate and adaptive immune response involving monocytes/macrophages, dendritic cells, natural killer(NK) cells, T cells. Among these immune cells, cell subsets with suppressive features have been recognized such as myeloid derived suppressive cells(MDSC),NK-reg, T-reg, which represent a critical regulatory system during liver fibrogenesis or tumourigenesis. However, the mechanisms that link HBVinduced immune dysfunction and HBV-related liver diseases are not understood.In this review we summarize the recent studies on innate and adaptive immune cell dysfunction in chronic HBV infection, liver fibrosis, cirrhosis, and HCC, and further discuss the potential mechanism of HBV-induced immunosuppressive cascade in HBV infection and consequences. It is hoped that this article will help ongoing research about the pathogenesis of HBV-related hepatic fibrosis and HBV-related HCC. | Tian-Yang Li Yang Yang Guo Zhou Zheng-Kun Tu | 2019 | World Journal of Gastroenterology2019，25，27： | 69 |
| 20 | Expression of nuclear factor-KB in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus显示文摘AIM In this study we investigated therelationship of the X protein of HBV and nuclearfactor-KB (NF-κB) and the expression of NF-KB inhuman hepatocellular carcinoma tissues.METHODS Immunohistochemistry SP methodwas used to detect the expression of NF-κB and the X protein of HBV in human hepatocellularcarcinoma tissues of 52 cases. Gene transfectionmediated by lipofectamine was used to transfectthe eukaryotic expression vector pCDNA3. 1-HBXof HBV x gene into human hepatocellularcarcinoma cell line HCC-9204 and NF-κB wasdetected.RESULTS NF-κB was widely expressed inhuman hepatocellular carcinoma tissues in atotal of 52 cases and its expression was relatedto the X protein of HBV. NF-KB was localizedboth in the cytoplasm and . The nuclei ofhepatocellular carcinoma cells in 11 cases whichwere positive for the X protein of HBV while in 41cases negative for the X protein of HBV, NF-Kbwas only localized in the cytoplasm ofhepatocellular carcinoma cells but translocatedto the nuclei of hepatocellular carcinoma cellsafter the eukaryotic expression vectorpCDNA3.1-HBX was transfected into HCC-9204cells.CONCLUSION This study strongly suggeststhat the nuclear factor NF-KB is widely expressedin hepatocellular carcinoma tissues in differentstyles according to the expression of the Xprotein of HBV. NF-κB is abnormally activated inhepatocellular carcinoma, which is probablyrelated to the X protein of HBV. The X protein ofHBV can activate NF-κB to translocate into nucleiof hepatocellular carcinoma cells. | Shuang Ping Guo~1 Wen Liang Wang~1 Yu Qiang Zhai~2 Yi Ling Zhao~1 ~1Department of Pathology,Xijing Hospital of the Fourth Military Medical University,Xi’an,China ~2Department of Urology,the Central Hospital of Xi’an,China | 2001 | World Journal of Gastroenterology2001，7，3： | 55 |
您所在的机构暂未开通此部分的功能，请联系管理员